- Home
- SABS vs MFIN Comparison
SABS vs MFIN Comparison
Compare SABS & MFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SABS | MFIN |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | 86 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.8M | 240.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SABS | MFIN |
|---|---|---|
| Price | $3.86 | $9.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $10.75 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 996.7K | 52.5K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 5.18% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.02 |
| P/E Ratio | ★ N/A | $6.21 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $7.85 |
| 52 Week High | $6.60 | $11.00 |
Technical Indicators
Market Signals| Indicator | SABS | MFIN |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 55.14 |
| Support Level | $3.54 | $9.13 |
| Resistance Level | $4.11 | $10.14 |
| Average True Range (ATR) | 0.35 | 0.30 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 39.42 | 70.71 |
Price Performance
Historical ComparisonAbout SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.